Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib in Pediatric Patients With Ph+ CML-CP
NCT04925479Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Dec 2021
- Primary completion
- Sep 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 14
01
Overview
Phase 2, open-label trial of asciminib in chronic myeloid leukemia (CML) (2 arms), sponsored by Novartis. Primary endpoints: Area Under the Curve from time zero to the last quantifiable concentration at 52 weeks and Area Under the Curve over the dosing interval at 52 weeks. Started Dec 2021; status: recruiting.
02
Drugs
asciminib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04925479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04925479.